Biotech Showcase 2019: Targeting Tau To Tackle Neurodegenerative Diseases
Executive Summary
Asceneuron CEO Dirk Beher tells Mike Ward about the progress that the 2012 startup is making with its small-molecule therapeutics that reduce the accumulation of toxic aggregates of the tau protein into the neurofibrillary tangles.